Classical homocystinuria - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

CVS stock slips as Aetna settles Medicare Advantage diagnosis code fraud case for $117.7m

What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)

CVGI surges 54% as CVG names Zoox strategic supplier and issues $700M revenue outlook for 2026

Representative image illustrating rising takeover speculation around Papa John’s International, Inc., as renewed private equity interest and a reported $65-per-share bid from TriArtisan Capital Advisors push the PZZA stock back into focus amid ongoing turnaround efforts.

Papa John’s agrees to explore sale as renewed private equity interest lifts PZZA

Read More

2 minute read

Pharma Industry News

Swiss pharma Orphan Technologies launches phase 1/2 clinical trial for OT-58 in classical homocystinuria

Orphan Technologies, a Swiss pharmaceutical company, has officially dosed the first patients in its groundbreaking phase 1/2 clinical…

bypharmanewsdaily

February 16, 2019

web analytics